Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JATT NASDAQ:MTEX NASDAQ:OVID NASDAQ:RNAZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJATTJATT Acquisition$1.35+12.5%$1.16$7.80▼$12.38$23.29MN/A41,322 shs2.01 million shsMTEXMannatech$8.77-3.6%$9.76$7.00▼$16.49$17.30M0.896,049 shs4,221 shsOVIDOvid Therapeutics$0.42-4.2%$0.31$0.24▼$1.47$31.10M0.13448,725 shs672,421 shsRNAZTransCode Therapeutics$9.00-1.4%$8.07$6.15▼$905.52$7.60M1.4104,372 shs29,557 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJATTJATT Acquisition+6.19%+14.29%-4.76%-1.64%-66.67%MTEXMannatech+2.44%-5.38%-17.11%+3.67%+18.83%OVIDOvid Therapeutics+1.72%+32.34%+32.07%+71.53%-47.29%RNAZTransCode Therapeutics-1.30%+10.13%+21.73%-18.20%-99.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech0.2897 of 5 stars0.03.00.00.00.61.70.0OVIDOvid Therapeutics4.2156 of 5 stars3.63.00.04.60.62.50.6RNAZTransCode Therapeutics2.0603 of 5 stars3.54.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJATTJATT Acquisition 0.00N/AN/AN/AMTEXMannatech 0.00N/AN/AN/AOVIDOvid Therapeutics 3.20Buy$3.13645.82% UpsideRNAZTransCode Therapeutics 3.00Buy$280.003,011.11% UpsideCurrent Analyst Ratings BreakdownLatest RNAZ, JATT, OVID, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.504/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$560.00 ➝ $280.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/AMTEXMannatech$117.87M0.14$2.06 per share4.26$4.57 per share1.92OVIDOvid Therapeutics$570K52.27N/AN/A$0.96 per share0.44RNAZTransCode TherapeuticsN/AN/AN/AN/A($54.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMTEXMannatech$2.49M-$0.10N/A∞N/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)RNAZTransCode Therapeutics-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%N/ALatest RNAZ, JATT, OVID, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJATTJATT AcquisitionN/AN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJATTJATT AcquisitionN/A0.150.15MTEXMannatech0.461.180.65OVIDOvid Therapeutics0.224.934.93RNAZTransCode TherapeuticsN/A5.205.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJATTJATT Acquisition47.97%MTEXMannatech12.98%OVIDOvid Therapeutics72.24%RNAZTransCode TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipJATTJATT Acquisition20.00%MTEXMannatech41.50%OVIDOvid Therapeutics13.10%RNAZTransCode Therapeutics0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMTEXMannatech2501.90 million1.11 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableRNAZTransCode Therapeutics9833,000832,000Not OptionableRNAZ, JATT, OVID, and MTEX HeadlinesRecent News About These CompaniesTranscode Therapeutics Inc News (RNAZ) - Investing.comJuly 4, 2025 | investing.comTransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory BoardMay 28, 2025 | prnewswire.comTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities ReportedMay 8, 2025 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 6, 2025 | finanznachrichten.deTransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 5, 2025 | prnewswire.comTransCode Therapeutics approves reverse stock split to meet Nasdaq rulesMay 4, 2025 | investing.comTransCode reports progress in metastatic cancer trialMay 3, 2025 | uk.investing.comTransCode Therapeutics Announces 1-for-28 Reverse Stock SplitMay 2, 2025 | prnewswire.comIBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | finance.yahoo.comTransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138May 2, 2025 | financial-news.co.ukTransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic CancerMay 1, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingApril 21, 2025 | prnewswire.comAll You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to BuyApril 18, 2025 | zacks.comTranscode Therapeutics price target lowered to $10 from $20 at H.C. WainwrightApril 17, 2025 | markets.businessinsider.comTranscode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trialMarch 28, 2025 | markets.businessinsider.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 28, 2025 | finanznachrichten.deTransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138March 27, 2025 | prnewswire.comTransCode Therapeutics, Inc. Announces Closing of Registered Direct OfferingMarch 25, 2025 | prnewswire.comTranscode to sell 10.25M shares at 98c per share in registered direct offeringMarch 25, 2025 | markets.businessinsider.comTransCode Therapeutics stock slides after announces to raise $10M securities offeringMarch 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksThe Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldBy Jeffrey Neal Johnson | June 22, 2025View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsAstera Labs: AI Infrastructure Play With Significant Growth AheadBy Nathan Reiff | June 26, 2025View Astera Labs: AI Infrastructure Play With Significant Growth AheadRNAZ, JATT, OVID, and MTEX Company DescriptionsJATT Acquisition NYSE:JATT$1.35 +0.15 (+12.50%) As of 07/9/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Mannatech NASDAQ:MTEX$8.77 -0.33 (-3.64%) Closing price 03:50 PM EasternExtended Trading$8.77 +0.00 (+0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Ovid Therapeutics NASDAQ:OVID$0.42 -0.02 (-4.21%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.02 (+3.82%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.TransCode Therapeutics NASDAQ:RNAZ$9.00 -0.13 (-1.42%) Closing price 04:00 PM EasternExtended Trading$8.90 -0.10 (-1.06%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
